论文部分内容阅读
目的:重点探索采用顺铂和培美曲塞两种药物治疗非小细胞肺癌的疗效。方法:选取的研究对象是2011年1月初至2013年12月底在我院接受治疗的46例非小细胞肺癌患者,将患者随机分成两组,单独采用培美曲塞治疗23例对照组患者,同时采用顺铂和培美曲塞两种药物治疗23例观察组患者,对比疗效。结果:对照组的治疗效果较差,总有效率仅能达到78.26%。观察组的治疗效果较好,总有效率可达95.65%。观察组的治疗效果显然优于对照组。对照组的不良反应发生率为21.74%,观察组的不良反应发生率为8.70%,观察组的不良反应显著少于对照组。结论:采用顺铂和培美曲塞两种药物治疗非小细胞肺癌的疗效较好,而且毒副作用较少,安全性较高,值得推荐。
Objective: To explore the use of cisplatin and pemetrexed two drugs in the treatment of non-small cell lung cancer. Methods: Forty-six non-small cell lung cancer patients treated in our hospital from the beginning of January 2011 to the end of December 2013 were selected and randomly divided into two groups. Pemetrexed alone was used in the treatment of 23 patients with the control group, In the meantime, 23 patients in observation group were treated with cisplatin and pemetrexed, and the curative effect was compared. Results: The control group was less effective and the total effective rate was only 78.26%. Observation group’s treatment effect is better, the total efficiency up to 95.65%. The observation group’s treatment effect is obviously better than the control group. The incidence of adverse reactions in the control group was 21.74%, the incidence of adverse reactions in the observation group was 8.70%, and the adverse reactions in the observation group were significantly less than those in the control group. Conclusion: Both cisplatin and pemetrexed treatment of non-small cell lung cancer have better curative effect, fewer side effects and higher safety, which is worth recommending.